65,437 trials
Locally Advanced Thymic Carcinoma · Metastatic Thymic Carcinoma · Recurrent Thymic Carcinoma
Primary: Progression-free Survival — 8; 7 Months
Mathematics Abilities
Primary: Change in Flexible Attention to Magnitudes Task — .07; .13; .03; .08 mean pre-post diff in units on a scale — p=.41
Renal Colic · Kidney Stone
Primary: Participants Who Received a Second Parenteral Pain Medication in the Emergency Department (ED) — 0 Participants
Epilepsy
Primary: Percentage of Subjects Completing Screening Instruments — 0; 14; 19; 12 Percentage who completed
Multiple Sclerosis · Fatigue
Primary: Modified Fatigue Inventory Scale (MFIS) — 46.5; 55.2; 54.3; 45.1 units on a scale — p=0.9489
Melanoma
Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 3; 3; 4 participants
Osteoporosis
Primary: Change in Whole Body Bone Mineral Content (BMC) — 20.1; 18.6; 17.3; 20.7 grams — p=0.377
Stress Urinary Incontinence
Primary: Time Interval Between End of Surgery and First Void — 183; 197 minutes — p=0.40
Post-operative Pain
Primary: Epidural Catheter Failure — 52; 51 Participants
Aneurysmal Subarachnoid Hemorrhage
Primary: Cerebrospinal Fluid 3-aminopropanal (CSF-3AP) Levels — 11.1; 12.9 nmol/mL
Smoking, Cigarette
Primary: Quit Smoking Motivation — 3.7; 3.9; 3.7 score on a scale
Pantothenate Kinase-Associated Neurodegeneration
Primary: Number of Treatment-emergent Adverse Events Assessed Using CTCAE v4.0 — 1.15; 1.38; 1.14; 0.86 Events per person — p=0.50
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale (HAM-D) — 20.4375; 21.7692; 11.3333; 11.9231 score on a scale
Stress Disorders, Traumatic · Stress Disorders, Traumatic, Acute · Depressive Symptoms
Primary: Housing Stability — 17; 65; 7; 23 Participants
CSF Circulation
Primary: CSF Flow Velocities — 1.36; 1.31; 1.48; 1.15 cm/s